EcoDrugPlus

Phospholipase A2 Group Vii

Ensembl ID : ENSBSLG00000021393
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSBSLG00000020608
Gene Symbol: LOC114860591
3 Cross references
233 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSBSLG00000002276
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSBSLG00000012684
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Plasminogen-Like

Ensembl ID : ENSBSLG00000022891
Gene Symbol: LOC114849358
3 Cross references
211 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSBSLG00000021350
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSBSLG00000001662
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSBSLG00000018102
Gene Symbol: PDGFRB
3 Cross references
199 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSBSLG00000019333
Gene Symbol: LOC114869682
2 Cross references
174 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSBSLG00000002512
Gene Symbol: PLK1
3 Cross references
187 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSBSLG00000018127
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSBSLG00000018953
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).